Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB, a pan-HER inhibitor for non-small cell lung cancer tumors; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly to hospitals and cancer centers in the United States; and through distributors in Europe. It has a strategic partnership with Servier Canada, Inc.; licensing and development agreement with Cell Therapeutics, Inc.; license agreements with Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc., and Mundipharma International Corporation Limited; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd and The University of Texas MD Anderson Cancer Center. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Underperform Votes

Community Sentiment

Spectrum Pharmaceuticals has received 56.35% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote “Outperform” if you believe SPPI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.

1.0 Company Ownership

In the past three months, Spectrum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,522.00 in company stock.

Miscellaneous

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

How has Spectrum Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Spectrum Pharmaceuticals' stock was trading at $2.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SPPI shares have increased by 28.9% and is now trading at $3.08. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spectrum Pharmaceuticals.

What price target have analysts set for SPPI?

4 brokerages have issued 12 month price targets for Spectrum Pharmaceuticals' shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate Spectrum Pharmaceuticals' stock price to reach $7.67 in the next twelve months. This suggests a possible upside of 148.9% from the stock's current price. View analysts' price targets for Spectrum Pharmaceuticals.

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

News articles about SPPI stock have been trending somewhat negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Spectrum Pharmaceuticals earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutSpectrum Pharmaceuticals.

Which major investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, BlackRock Inc., Nuveen Asset Management LLC, Bank of New York Mellon Corp, Russell Investments Group Ltd., Arizona State Retirement System, Legal & General Group Plc, and Sargent Investment Group LLC. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Thomas J Riga, and William Ashton. View insider buying and selling activity for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $3.08.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $358.73 million and generates $109.33 million in revenue each year. The biotechnology company earns $-112,690,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.